Skip to content
OpenCapital
Get started

Amphastar Pharmaceuticals AMPH G&A

G&A at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$26.2M+85.4%

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M—
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.3%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's G&A?
Amphastar Pharmaceuticals (AMPH) reported G&A of $18.03M in Q1 2026.
How has Amphastar Pharmaceuticals's G&A changed year-over-year?
Amphastar Pharmaceuticals's G&A increased by 12.7% year-over-year, from $16M to $18.03M.
What is the long-term trend for Amphastar Pharmaceuticals's G&A?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's G&A has grown at a 13.7% compound annual growth rate (CAGR), from $51.43M to $85.93M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.